BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/8/2017 1:51:46 AM | Browse: 1013 | Download: 1538
 |
Received |
|
2017-02-14 08:56 |
|
Peer-Review Started |
|
2017-02-14 17:43 |
|
To Make the First Decision |
|
2017-04-14 10:31 |
|
Return for Revision |
|
2017-04-19 15:11 |
|
Revised |
|
2017-05-13 03:49 |
|
Second Decision |
|
2017-05-16 02:11 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2017-05-24 00:47 |
|
Articles in Press |
|
2017-05-24 00:47 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2017-08-03 03:48 |
|
Publish the Manuscript Online |
|
2017-08-08 01:51 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Minireviews |
| Article Title |
Use of programmed cell death protein ligand 1 assay to predict the outcomes of non-small cell lung cancer patients treated with immune checkpoint inhibitors
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Carmelo Tibaldi, Alice Lunghi and Editta Baldini |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Dr. Carmelo Tibaldi, Division of Oncology, Department of Oncology, S. Luca Hospital, Via Guglielmo Lippi Francesconi 1, 55100 Lucca, Italy. carmelo.tibaldi@uslnordovest.toscana.it |
| Key Words |
Predictive biomarkers; Immunotherapy; Checkpoint inhibitors; Programmed cell death protein ligand 1; Non-small cell lung cancer |
| Core Tip |
Use of programmed cell death protein ligand 1 (PD-L1) assay to predict the outcomes of non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors. This minireview underlines promises and pitfalls of the PD-L1 expression to predict the activity and efficacy of programmed cell death protein 1/PD-L1 inhibitors in NSCLC. |
| Publish Date |
2017-08-08 01:51 |
| Citation |
Tibaldi C, Lunghi A, Baldini E. Use of programmed cell death protein ligand 1 assay to predict the outcomes of non-small cell lung cancer patients treated with immune checkpoint inhibitors. World J Clin Oncol 2017; 8(4): 320-328 |
| URL |
http://www.wjgnet.com/2218-4333/full/v8/i4/320.htm |
| DOI |
http://dx.doi.org/10.5306/wjco.v8.i4.320 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
